(Q41535324)

2 October 2017

1 reference

title

Acquired motor neuron disorders (English)

1 reference

2 October 2017

Ross MA

1

1 reference

2 October 2017

publication date

1 August 1997

1 reference

2 October 2017

1 reference

2 October 2017

volume

15

1 reference

2 October 2017

issue

3

1 reference

2 October 2017

page(s)

481-500

1 reference

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Evidence for autoimmunity in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

A rating scale for amyotrophic lateral sclerosis: description and preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Clinical and genetic variations in the syndrome of adult GM2 gangliodosis resulting from hexosaminidase a deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

ALS, SOD and peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Motor neurone disease as a manifestation of neoplasm (with a note on the course of classical motor neurone disease).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Late denervation in patients with antecedent paralytic poliomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Multifocal motor neuropathy: response to human immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Oxidative stress, glutamate, and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

The pharmacology and mechanism of action of riluzole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Motor neuron growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Pyramidal tract deficits and polyneuropathy in hyperthyroidism, Combination clinically mimicking amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Neuropathology of ALS: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Management of ALS: respiratory care

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Enterovirus and Mumps Virus Infections of the Nervous System

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Rising mortality from motoneuron disease in the USA, 1962-84.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Motor neurone disease and hyperthyroid Graves' disease: a chance association?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Heavy metals and trace elements in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Motor neuron disease (ALS): evaluation of detection thresholds of cutaneous sensation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Onset, natural history and outcome in idiopathic adult motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Proteolytic activity in amyotrophic lateral sclerosis IgG preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Skin abnormalities and autonomic involvement in the early stage of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Excitotoxicity hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Postradiation motor neuron syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Molecular genetic basis of familial ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Progressive motor neuron disease associated with electrical injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Autoimmunity and ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Dysphagia in patients with the post-polio syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Segmental zoster paresis--a disease profile

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Anticholinesterase-responsive neuromuscular junction transmission defects in post-poliomyelitis fatigue

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels--new doubts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Lack of progression of neurologic deficit in survivors of paralytic polio: a 5-year prospective population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Classic amyotrophic lateral sclerosis with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Primary lateral sclerosis. A clinical diagnosis reemerges

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970330-3

7 January 2021

10.1016/S0733-8619(05)70330-3

Identifiers

DOI

1 reference

2 October 2017

1 reference